Clinical Trial Update: A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants [Phase 4]

View source ↗

Summary

Phase 4 post-marketing study evaluating long-term efficacy and safety of osmotic-release methylphenidate in ADHD participants; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• CONCERTA (METHYLPHENIDATE HYDROCHLORIDE)

Snippet

Sponsor: Xian-Janssen Pharmaceutical Ltd. | Conditions: Attention Deficit Hyperactivity Disorder (ADHD) | Phase 4 | Status: COMPLETED | Results posted: 2014-09-17